923281-64-5

Usage

Uses

Used in Pharmaceutical Research:
(5-Bromo-4-fluoro-2-methoxyphenyl)methanol is used as an intermediate in organic synthesis for the development of new pharmaceuticals. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, (5-Bromo-4-fluoro-2-methoxyphenyl)methanol is utilized as a key intermediate in the synthesis of various agrochemicals, contributing to the development of effective products for agricultural use.
Used in Specialty Chemicals:
(5-Bromo-4-fluoro-2-methoxyphenyl)methanol is used as a building block in the production of specialty chemicals, including dyes, perfumes, and flavoring agents. Its versatility in chemical reactions enables the creation of a diverse array of products with specific properties and applications.
Used in Drug Discovery and Development:
Due to its biological activity and potential medicinal properties, (5-Bromo-4-fluoro-2-methoxyphenyl)methanol is a subject of interest in drug discovery and development. Researchers are exploring its potential applications in creating new drugs and therapies for various medical conditions.

Upstream product

• 314298-22-1 5-bromo-4-fluoro-2-methoxy-benzoic acid methyl ester 
• 95383-26-9 5-bromo-4-fluoro-2-methoxybenzoic acid 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST

The present invention relates to a compounds represented by the formula. The compounds of the present invention have a superior tachykinin receptor antagonistic action, particularly a substance P receptor antagonistic action, and is useful as pharmaceutical agents, for example, tachykinin receptor antagonists, agents for the prophylaxis or treatment of lower urinary tract symptoms, gastrointestinal diseases or central nerve diseases.

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.